Cargando…

Engineered EGCG‐Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy

Nano‐based immunotherapy of therapeutic biomolecules is attractive but tremendously hampered by the poor delivery efficiency. This study reports a novel delivery system of fluorinated‐coordinative‐epigallocatechin gallate (EGCG), referring as FEGCG/Zn, through the integration of fluorination and zin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Pengkai, Zhang, Haitian, Yin, Yin, Sun, Meiling, Mao, Shuai, Chen, Huihui, Deng, Yexuan, Chen, Shuai, Li, Shuo, Sun, Beicheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131592/
https://www.ncbi.nlm.nih.gov/pubmed/35486032
http://dx.doi.org/10.1002/advs.202105894
_version_ 1784713205211201536
author Wu, Pengkai
Zhang, Haitian
Yin, Yin
Sun, Meiling
Mao, Shuai
Chen, Huihui
Deng, Yexuan
Chen, Shuai
Li, Shuo
Sun, Beicheng
author_facet Wu, Pengkai
Zhang, Haitian
Yin, Yin
Sun, Meiling
Mao, Shuai
Chen, Huihui
Deng, Yexuan
Chen, Shuai
Li, Shuo
Sun, Beicheng
author_sort Wu, Pengkai
collection PubMed
description Nano‐based immunotherapy of therapeutic biomolecules is attractive but tremendously hampered by the poor delivery efficiency. This study reports a novel delivery system of fluorinated‐coordinative‐epigallocatechin gallate (EGCG), referring as FEGCG/Zn, through the integration of fluorination and zinc ions (Zn(2+)) into EGCG. The robust therapeutics of FEGCG/Zn are measured in terms of the regulating effect on programmed cell death ligand 1 (PD‐L1), the effective delivery of diverse biomolecules, and the hitchhiking ability using living cells. Taking small interfering RNA of PD‐L1 (siPD‐L1) and erythrocytes as an example, the fabricated biomimetic system achieves excellent siPD‐L1 delivery and further improves siPD‐L1 accumulation in tumors. Finally, the combination of FEGCG/Zn and siPD‐L1 promotes antitumor immunotherapy through alleviation of T cells exhaustion by regulating PD‐L1 expression in tumor cells. The results demonstrate that FEGCG/Zn substantially regulates PD‐L1 expression and improves immune‐biomolecule delivery by forming biomimetic nanoassemblies, offering a versatile platform for cancer immunotherapy.
format Online
Article
Text
id pubmed-9131592
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91315922022-05-26 Engineered EGCG‐Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy Wu, Pengkai Zhang, Haitian Yin, Yin Sun, Meiling Mao, Shuai Chen, Huihui Deng, Yexuan Chen, Shuai Li, Shuo Sun, Beicheng Adv Sci (Weinh) Research Articles Nano‐based immunotherapy of therapeutic biomolecules is attractive but tremendously hampered by the poor delivery efficiency. This study reports a novel delivery system of fluorinated‐coordinative‐epigallocatechin gallate (EGCG), referring as FEGCG/Zn, through the integration of fluorination and zinc ions (Zn(2+)) into EGCG. The robust therapeutics of FEGCG/Zn are measured in terms of the regulating effect on programmed cell death ligand 1 (PD‐L1), the effective delivery of diverse biomolecules, and the hitchhiking ability using living cells. Taking small interfering RNA of PD‐L1 (siPD‐L1) and erythrocytes as an example, the fabricated biomimetic system achieves excellent siPD‐L1 delivery and further improves siPD‐L1 accumulation in tumors. Finally, the combination of FEGCG/Zn and siPD‐L1 promotes antitumor immunotherapy through alleviation of T cells exhaustion by regulating PD‐L1 expression in tumor cells. The results demonstrate that FEGCG/Zn substantially regulates PD‐L1 expression and improves immune‐biomolecule delivery by forming biomimetic nanoassemblies, offering a versatile platform for cancer immunotherapy. John Wiley and Sons Inc. 2022-03-25 /pmc/articles/PMC9131592/ /pubmed/35486032 http://dx.doi.org/10.1002/advs.202105894 Text en © 2022 The Authors. Advanced Science published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Wu, Pengkai
Zhang, Haitian
Yin, Yin
Sun, Meiling
Mao, Shuai
Chen, Huihui
Deng, Yexuan
Chen, Shuai
Li, Shuo
Sun, Beicheng
Engineered EGCG‐Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy
title Engineered EGCG‐Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy
title_full Engineered EGCG‐Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy
title_fullStr Engineered EGCG‐Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy
title_full_unstemmed Engineered EGCG‐Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy
title_short Engineered EGCG‐Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy
title_sort engineered egcg‐containing biomimetic nanoassemblies as effective delivery platform for enhanced cancer therapy
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131592/
https://www.ncbi.nlm.nih.gov/pubmed/35486032
http://dx.doi.org/10.1002/advs.202105894
work_keys_str_mv AT wupengkai engineeredegcgcontainingbiomimeticnanoassembliesaseffectivedeliveryplatformforenhancedcancertherapy
AT zhanghaitian engineeredegcgcontainingbiomimeticnanoassembliesaseffectivedeliveryplatformforenhancedcancertherapy
AT yinyin engineeredegcgcontainingbiomimeticnanoassembliesaseffectivedeliveryplatformforenhancedcancertherapy
AT sunmeiling engineeredegcgcontainingbiomimeticnanoassembliesaseffectivedeliveryplatformforenhancedcancertherapy
AT maoshuai engineeredegcgcontainingbiomimeticnanoassembliesaseffectivedeliveryplatformforenhancedcancertherapy
AT chenhuihui engineeredegcgcontainingbiomimeticnanoassembliesaseffectivedeliveryplatformforenhancedcancertherapy
AT dengyexuan engineeredegcgcontainingbiomimeticnanoassembliesaseffectivedeliveryplatformforenhancedcancertherapy
AT chenshuai engineeredegcgcontainingbiomimeticnanoassembliesaseffectivedeliveryplatformforenhancedcancertherapy
AT lishuo engineeredegcgcontainingbiomimeticnanoassembliesaseffectivedeliveryplatformforenhancedcancertherapy
AT sunbeicheng engineeredegcgcontainingbiomimeticnanoassembliesaseffectivedeliveryplatformforenhancedcancertherapy